

获得全面许可的瑞士大麻 GACP 种植和 GMP 生产能力



MERGERSCORP

GACP GMP

瑞士一家拥有罕见的大麻和医用大麻生产许可证的公司正在出售。

公司的宗旨是 以及 .

公司可在国内外设立分公司和子公司，参股国内外其他公司，收购、持有、利用和出售知识产权，以及开展与其宗旨直接或间接相关的所有业务。 .

公司可以收购、抵押、出售和管理国内外的房地产。 .

它还可以为自己或第三方账户进行融资，并为子公司和第三方提供担保和保证。 .

许可证/授权

公司拥有瑞士医用大麻行业所需的所有许可证。

有了这些许可证，该公司可以在瑞士境内直接种植、储存、采购、进口、交易、委托和分销其产品。

这些许可证由瑞士治疗产品授权和监管机构 Swissmedic 颁发。

生产设施经过了州药剂师的检查和批准，并获得了地区药品研究所（RHI）GMP（药品生产质量管理规范）部门的批准，从而满足了运营的所有监管要求。

生产领域

多室栽培设施，包括专门的母株栽培区，可实现稳定的制药级生产。

经销商/网络

通过对整个生产链和批发贸易的控制，该公司拥有进入整个瑞士医用和药用大麻市场的独特机会。

- **1.8x** 显著的商业增长奠定了坚实的基础。

我们通过瑞士领先的药店渠道成功打入了早期市场，这表明我们的商业模式已做好市场准备，并支持在全国范围内推广。

业务执行将由一位领导，他在药房行业拥有成熟的网络。

此人将具体负责建立和管理分销渠道。

为了确保最大限度地渗透市场，我们目前正在评估这一合作的最佳结构-是作为独立中介机构，还是通过长期雇用合同。

- 与 B2B 药品批发商（如 Galexis and Co.）

TARGET PRICE

\$ 0

BUSINESS TYPE

制造业

COUNTRY

瑞士

BUSINESS ID

L#20251050

许可证

原创 英语

Betriebsbewilligung zum Anbau von Cannabis für medizinische Zwecke.

(Art. 2 Bst. h BetmKV) (《麻醉品管制条例》第 2 条 h 款)

-Betriebsbewilligung zum Umgang mit kontrollierten Substanzen.

(Art. 2 Bst. h BetmKV) (《麻醉品管制条例》第 2 条 h 款)

(Bewilligungsnummer XXXXXX-XXXXXX) (许可证编号: XXXXXX-XXXXXX)

- Arzneimitteln 的制造

- 医药产品的生产

- 装有艺术品的手推车

- 医药产品批发

- 德国电信法 (HMG; SR 812.21)

- 《治疗产品法》 (HMG; SR 812.21)

- Arzneimittel-Bewilligungsverordnung (AMBV; SR 812.212.1)

- 《医药产品许可条例》 (AMBV; SR 812.212.1)

- Arzneimittelverordnung (VAM; SR 812.212.21)

- 《医药产品条例》 (VAM; SR 812.212.21)

- 根据《医疗保险法》 (HMG) 制定的条例 根据《治疗产品法》 (HMG) 进行合同生产 (“oll “生产)

基础设施

该公司通过租赁场地和充分利用现有基础设施, 实现了低成本高效率的生产。

其房东最近向其提出了在大楼内租赁更多空间的可能性。

已经以非常优惠的条件签订了为期 10 年的租赁协议。

人力资源

有 2 名员工和 3 名自由职业者。其团队已成立 10 年, 拥有丰富的经验。

快速可扩展性

凭借现有的技术诀窍和租赁更多生产空间的可能性, 公司可以快速响应需求。

瑞士制造

这使它能够以高品质的鲜花进入国际市场。

据公司所知, 目前在全球市场上还没有一家瑞士公司拥有自己的产品。

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

MERGERSCORP

WWW.MERGERSCORP.COM